Key Finding: Regulatory Agencies Split on New Alzheimer’s Drugs as Hope Meets Uncertainty

GMJ
By
Prof. Giorgi Pkhakadze
0 Min Read
Regulatory agencies reviewing Alzheimer's disease treatment approvals with conflicting decisions
Regulatory agencies worldwide are delivering conflicting assessments of novel Alzheimer's treatments, creating uncertainty for millions of patients. The Lancet examines divergent approval pathways and their implications for global access. — Photo: SHVETS production / Pexels
1 min read|38 words

55 million people worldwide live with dementia, yet new Alzheimer's treatments face conflicting regulatory decisions across different countries. Some agencies approve based on biomarker changes while others demand functional improvement evidence.

Read the full article on GMJ Newsroom →

Was this article helpful?

Share This Article
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
IOM Governance Structure Reinforces Global Migration Health Framework

IOM's governance structure demonstrates how 175 member countries coordinate migration health policies…

International migration law framework faces enforcement gaps, IOM legal analysis reveals

International migration law provides comprehensive legal frameworks for 281 million migrants worldwide,…

IOM Calls for Evidence-Based Innovation to Transform Migration Health Systems

IOM outlines comprehensive innovation framework to transform healthcare access for 281 million…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like